Lincoln Pharmaceuticals share news, announcements and annual reports
NSE: LINCOLNBSE: 531633Pharmaceuticals & BiotechnologySmall Cap
Lincoln Pharmaceuticals Limited · Face value ₹10 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed Apr 1996 on BSE, Dec 2015 on NSE
Last close ₹558.10up ₹8.05 (1.46%)BSE ₹557.55
Share price at the NSE close on 28 Oct 2026. Previous close ₹550.05.
28 Oct: open ₹541.00, high ₹560.00, low ₹532.00
52-week range of traded prices to 28 Oct 2026
₹440.00Low, 28 Jan 2026₹770.00High, 27 May 2026
- Next results date: the board meets on 29 Oct 2026 to consider: financial results. The notice · Results calendar
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹1,118 Cr1,389th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- 11.59
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 1.48
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 0.32%
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- 13.5%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 11.3%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026.
- 0.01
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day. Volume in the glossary
- 47,20541.0% delivered
Lincoln Pharmaceuticals has 352 announcements on record, routine notices left out; 5 in the 30 days to 28 Oct 2026, the latest on 22 Oct 2026.
Next board meeting and results date
As the company gave notice to the exchange.Lincoln Pharmaceuticals quarterly results
Oct29Thu
The board meets on 29 Oct 2026 to consider financial results
Notice filed 22 Oct 2026
To consider and approve the financial results for the period ended September 30, 2026
Lincoln Pharmaceuticals annual reports, presentations and earnings calls
The company's own documents, latest first.Lincoln Pharmaceuticals financials, year by year
Annual reports11
- Annual report, year to Mar 20265 Sep 2026
- Annual report, year to Mar 20256 Sep 2025
- Annual report, year to Mar 20246 Sep 2024
- Annual report, year to Mar 20236 Sep 2023, a zip file
- Annual report, year to Mar 20226 Sep 2022, a zip file
6 earlier reports
- Annual report, year to Mar 20217 Sep 2021, a zip file
- Annual report, year to Mar 20205 Sep 2020, a zip file
- Annual report, year to Mar 20195 Sep 2019, a zip file
- Annual report, year to Mar 20181 Oct 2018, a zip file
- Annual report, year to Mar 20175 Oct 2017, a zip file
- Annual report, year to Mar 20163 Oct 2016, a zip file
Investor presentations1
- Investor Presentation on Unaudited Financial Result for the Q1 - 2016-17 i.e. June 30, 2016.17 Aug 2016, a zip file
Earnings calls4
Lincoln Pharmaceuticals merger and demerger filings
Filings about a merger, demerger or scheme of arrangement, latest first.
Filings5
- Scheme of Arrangement of Lincoln Parenteral Limited ( Transferor Company ) and Lincoln Pharmaceuticals Limited ( Transferee Company ) and their respective shareholders and creditors vide its order dated September 14, 2021 and has been uploaded on the website of Hon'ble NCLT on September 15, 2021.16 Sep 2021
- Scheme of Arrangement, We enclosed herewith the copies of published newspaper publication with respect to notice of hearing of petition for sanctioning the scheme of arrangement between Lincoln Parenteral Limited ( the Transferor Company") and Lincoln Pharmaceuticals Limited ( the Transferee Company") and their respective shareholders and creditors, fixed for hearing before the Hon'ble Tribunal on March 31, 2021.23 Feb 2021
- Scheme of Arrangement Hon ble National Company Law Tribunal, Ahmedabad Bench in its order dated February 09, 2021 have directed the Company to publish newspaper publication and final hearing on said matter shall be appear on March 31, 2021.10 Feb 2021
- Scheme of Arrangement under regulation 30 an 37 of SEBI (LODR)7 Dec 2019
- Amalgamation/Merger pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 201519 Sep 2019
Lincoln Pharmaceuticals share news and announcements
Newest first. Page 1 of 8.
Oct 2026
22 Oct · Board meeting
17 Oct · Management
Sep 2026
30 Sep · Meeting
24 Sep · Management
24 Sep · Management
Aug 2026
29 Aug · Corporate action
13 Aug · Results
6 Aug · Board meeting
May 2026
28 May · Results
5 May · Format of the Annual Disclosure to be made by an entity identified as a LC - Annexure B2
Apr 2026
Feb 2026
12 Feb · Results
Jan 2026
10 Jan · Rating
7 Jan · Legal
Exchange has sought clarification from Lincoln Pharmaceuticals Limited for the quarter ended 30-Sep-2025 with respect to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company is required to clarify the following: -1. Financial results submitted is not as per format prescribed by SEBI The response of the Company is awaited.
Nov 2025
13 Nov · Results
Oct 2025
28 Oct · Meeting
Sep 2025
Aug 2025
29 Aug · Corporate action
7 Aug
7 Aug · Management
7 Aug · Results
Jul 2025
8 Jul · Management
2 Jul · General Updates
Jun 2025
23 Jun · Legal
Exchange has sought clarification from Lincoln Pharmaceuticals Limited for the quarter ended 31-Mar-2025 with respect to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company is required to clarify the following: -1. Segment details not submitted The response of the Company is awaited.
May 2025
22 May · Results
Apr 2025
Mar 2025
28 Mar
How the price met the news
The latest 30. The first session after each announcement, beside the market.
That dayThe first session's move. The first session's close after the announcement against the close before it, as a per cent change, on prices adjusted for splits and bonuses.Against the Nifty 500Against the Nifty 500. The share's move less the Nifty 500's move the same session, in percentage points (pts).Market median on that newsThe market's median move on that news. The middle first-session move of every listed company that filed the same kind of announcement, half moving more and half less.Five sessionsFive sessions' move. The close five sessions after the announcement against the close before it, as a per cent change.Five sessions against the Nifty 500Five sessions against the Nifty 500. The share's five-session move less the Nifty 500's move over the same five sessions, in percentage points (pts).Volume, times usualVolume, times usual. The session's shares traded divided by the average of the twenty sessions before it.Delivery against usualDelivery against usual. The share of the session's volume delivered into demat accounts, rather than bought and sold again the same day, less its average over the twenty sessions before, in percentage points (pts). Delivery against usual in the glossary
- 19 Oct 2026Board or managers changeddown 1.88%−0.9 pts vs Nifty 500market median 0.0% · five sessions −3.0% (0.0 pts vs Nifty 500) · volume 0.8× usual · delivery −4.2 pts against usual · The announcement
- 24 Sep 2026Board or managers changeddown 1.47%+0.2 pts vs Nifty 500market median 0.0% · five sessions −3.0% (+0.8 pts vs Nifty 500) · volume 0.5× usual · delivery +3.1 pts against usual · The announcement
- 13 Aug 2026Resultsup 4.50%+4.6 pts vs Nifty 500market median −0.7% · five sessions +2.8% (+4.0 pts vs Nifty 500) · volume 41.9× usual · delivery −43.6 pts against usual · The announcement
- 29 May 2026Resultsdown 16.51%−15.2 pts vs Nifty 500market median −0.7% · five sessions −18.3% (−16.2 pts vs Nifty 500) · volume 1.9× usual · delivery −0.2 pts against usual · The announcement
- 12 Feb 2026Resultsup 16.44%+17.0 pts vs Nifty 500market median −0.7% · five sessions +20.0% (+20.6 pts vs Nifty 500) · volume 77.6× usual · delivery −31.8 pts against usual · The announcement
- 12 Jan 2026Credit ratingdown 0.37%−0.6 pts vs Nifty 500market median 0.0% · five sessions −4.6% (−4.2 pts vs Nifty 500) · volume 0.8× usual · delivery +8.3 pts against usual · The announcement
- 13 Nov 2025Resultsdown 4.49%−4.4 pts vs Nifty 500market median −0.7% · five sessions +1.5% (+1.2 pts vs Nifty 500) · volume 14.4× usual · delivery −5.2 pts against usual · The announcement
- 1 Sep 2025Board or managers changedup 0.87%−0.2 pts vs Nifty 500market median 0.0% · five sessions +3.7% (+2.1 pts vs Nifty 500) · volume 0.1× usual · delivery +10.8 pts against usual · The announcement
- 7 Aug 2025Resultsup 13.17%+13.0 pts vs Nifty 500market median −0.7% · five sessions +2.5% (+2.4 pts vs Nifty 500) · volume 204.0× usual · delivery −48.3 pts against usual · The announcement
- 9 Jul 2025Board or managers changeddown 0.24%−0.2 pts vs Nifty 500market median 0.0% · five sessions −1.5% (−1.0 pts vs Nifty 500) · volume 0.6× usual · delivery +0.6 pts against usual · The announcement
20 earlier announcements
- 22 May 2025Resultsdown 9.21%−8.6 pts vs Nifty 500market median −0.7% · five sessions −9.2% (−9.4 pts vs Nifty 500) · volume 6.5× usual · delivery −8.2 pts against usual · The announcement
- 16 May 2024Dividenddown 4.63%−5.5 pts vs Nifty 500market median 0.0% · five sessions −5.5% (−7.9 pts vs Nifty 500) · volume 19.2× usual · delivery −31.7 pts against usual · The announcement
- 1 Apr 2024Board or managers changedup 2.03%+0.9 pts vs Nifty 500market median 0.0% · five sessions +5.2% (+2.9 pts vs Nifty 500) · volume 0.7× usual · delivery −6.2 pts against usual · The announcement
- 23 Feb 2024Board or managers changedup 8.61%+8.5 pts vs Nifty 500market median 0.0% · five sessions +0.9% (+1.9 pts vs Nifty 500) · volume 6.4× usual · delivery −10.5 pts against usual · The announcement
- 25 May 2023Dividenddown 10.85%−11.1 pts vs Nifty 500market median 0.0% · five sessions −13.7% (−15.3 pts vs Nifty 500) · volume 8.4× usual · delivery −16.1 pts against usual · The announcement
- 25 May 2023Board or managers changeddown 10.85%−11.1 pts vs Nifty 500market median 0.0% · five sessions −13.7% (−15.3 pts vs Nifty 500) · volume 8.4× usual · delivery −16.1 pts against usual · The announcement
- 10 Nov 2022Resultsup 1.72%+2.5 pts vs Nifty 500market median −0.7% · five sessions −0.6% (−1.2 pts vs Nifty 500) · volume 8.9× usual · delivery −25.2 pts against usual · The announcement
- 10 Aug 2022Board or managers changeddown 6.61%−6.6 pts vs Nifty 500market median 0.0% · five sessions −6.2% (−8.8 pts vs Nifty 500) · volume 3.6× usual · delivery +11.3 pts against usual · The announcement
- 21 Jul 2022Board or managers changeddown 0.57%−1.3 pts vs Nifty 500market median 0.0% · five sessions −5.3% (−6.0 pts vs Nifty 500) · volume 0.5× usual · delivery +6.4 pts against usual · The announcement
- 19 May 2022Dividenddown 7.81%−5.2 pts vs Nifty 500market median 0.0% · five sessions −14.2% (−11.8 pts vs Nifty 500) · volume 6.4× usual · delivery −3.4 pts against usual · The announcement
- 19 May 2022Resultsdown 7.81%−5.2 pts vs Nifty 500market median −0.7% · five sessions −14.2% (−11.8 pts vs Nifty 500) · volume 6.4× usual · delivery −3.4 pts against usual · The announcement
- 11 Nov 2021Resultsup 1.28%+2.0 pts vs Nifty 500market median −0.7% · five sessions −3.4% (−3.0 pts vs Nifty 500) · volume 1.9× usual · delivery −19.5 pts against usual · The announcement
- 10 Aug 2021Resultsdown 3.92%−3.6 pts vs Nifty 500market median −0.7% · five sessions −10.4% (−11.3 pts vs Nifty 500) · volume 2.2× usual · delivery −10.3 pts against usual · The announcement
- 25 May 2021Dividenddown 7.70%−7.7 pts vs Nifty 500market median 0.0% · five sessions −8.5% (−10.5 pts vs Nifty 500) · volume 2.1× usual · delivery −1.9 pts against usual · The announcement
- 22 Feb 2021Credit ratingdown 0.27%+1.5 pts vs Nifty 500market median 0.0% · five sessions +1.4% (+3.5 pts vs Nifty 500) · volume 1.0× usual · delivery +1.4 pts against usual · The announcement
- 2 Feb 2021Resultsdown 6.14%−8.5 pts vs Nifty 500market median −0.7% · five sessions −8.1% (−13.8 pts vs Nifty 500) · volume 5.7× usual · delivery −4.5 pts against usual · The announcement
- 3 Nov 2020Resultsup 0.48%−0.6 pts vs Nifty 500market median −0.7% · five sessions −2.4% (−8.5 pts vs Nifty 500) · volume 2.4× usual · delivery −15.7 pts against usual · The announcement
- 20 Aug 2020Resultsdown 0.06%+0.4 pts vs Nifty 500market median −0.7% · five sessions +3.4% (+1.8 pts vs Nifty 500) · volume 4.5× usual · delivery −14.3 pts against usual · The announcement
- 25 Jun 2020Resultsup 1.88%+1.8 pts vs Nifty 500market median −0.7% · five sessions −5.8% (−6.5 pts vs Nifty 500) · volume 4.0× usual · delivery −17.0 pts against usual · The announcement
- 28 Feb 2020Dividenddown 3.91%−0.3 pts vs Nifty 500market median 0.0% · five sessions −8.2% (−5.0 pts vs Nifty 500) · volume 0.8× usual · delivery +24.0 pts against usual · The announcement
Lincoln Pharmaceuticals results filing dates and deadlines
Listed companies must file quarterly results within 45 days, and the year's within 60.
Days to fileDays to file. The days from the period's end to the day the results reached the exchange.DeadlineDeadline, days. The days the rules allow from the period's end: 45 for a quarter or half year, and 60 for the year and the March quarter filed with it. A company that listed after the period ended has until 21 days after its listing where that is later.